#USA #New York #Class Action #Levi & Korsinsky #Unicycive Therapeutics

Unicycive Therapeutics Faces Class Action Lawsuit

Investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) are in for a challenging period as the company finds itself embroiled in a securities class action lawsuit. Filed by Levi & Korsinsky, LLP, the lawsuit names prominent executives from the company, including Chief Executive Officer Shalabh Gupta and Chief Financial Officer John Townsend, as individual defendants. The legal action asserts that these leaders made misleading statements about the company's efforts in achieving compliance with the FDA through their third-party manufacturing vendor.

Background of the Lawsuit

The lawsuit arises from events that transpired between December 29, 2025, and June 29, 2026, during which Unicycive's stock faced a dramatic decline. On June 29, 2026, the stock closed at $7.70, only to crash to $4.69 the following trading day after the announcement of a second Complete Response Letter (CRL) from the FDA. This shockingly steep decline of 39.1% has prompted shareholders to seek legal redress for their losses.

The lawsuit claims that during the time period in question, Unicycive's leadership misrepresented the company’s manufacturing vendor's compliance status, asserting “significant progress” toward FDA compliance without having verified this through their own inspection. The allegations highlight potential violations of Section 20(a) of the Securities Exchange Act, establishing the executives' control over the disclosures made to the public.

Corporate Responsibilities

Under the Sarbanes-Oxley Act, executives are required to certify the accuracy of their company's filings. The complaint emphasizes the personal liability these officers face regarding omissions or misleading statements about the vendor’s compliance. Allegations indicate these executives failed to adequately oversee the information disseminated to investors and analysts, which misled shareholders about the state of the company and its compliance with regulations.

Implications of the Lawsuit

This class action lawsuit raises fundamental questions about corporate governance and accountability in publicly traded companies. Investors who purchased shares within the specified class period and faced financial losses may be eligible to reclaim some of their investments. Levi & Korsinsky is encouraging affected shareholders to evaluate their records to determine their eligibility, urging them to take immediate action, especially with the November 2, 2026 deadline for lead plaintiff applications looming.

What's Next for Investors?

Affected shareholders are advised to compile their brokerage records which should include purchase dates, share quantities, and prices paid for their Unicycive shares. Importantly, even those who have sold their shares at a loss during this class period are still eligible for participation in the lawsuit. The premises of the action rely on when shares were purchased rather than their current ownership status.

Lead plaintiffs—investors with the most significant financial losses—will represent the interests of all shareholders, overseeing how the case progresses. However, it is essential to note that participation in this class action does not require shareholders to attend court or provide testimony; most processes are handled through submission of claim forms.

Conclusion

The unfolding lawsuit against Unicycive Therapeutics underscores the precarious nature of investor trust and corporate transparency. As the company navigates these turbulent waters, shareholders must remain vigilant about their rights and options moving forward. For those looking to reclaim losses incurred during the identified timeframe, contacting Levi & Korsinsky could provide a pathway toward financial recovery. Investors should act swiftly in light of the approaching deadlines and potential for resolution in this significant case.